Growth Disorders and Skeletal Dysplasias
BioMarin Pharmaceutical Inc. focuses heavily on conditions affecting linear growth and bone development, including achondroplasia, hypochondroplasia, idiopathic short stature, Turner syndrome, short stature homeobox-containing gene deficiency, and Noonan syndrome. Its research also extends to pediatric growth impairment linked to inadequate response to human growth hormone.
- Achondroplasia
- Hypochondroplasia
- Idiopathic Short Stature
- Turner Syndrome
- Noonan Syndrome
The sponsor’s clinical activity in this area includes children, infants, and adolescents, with a strong emphasis on growth-related outcomes and long-term treatment experience.
Duchenne Muscular Dystrophy
BioMarin also invests in research for Duchenne muscular dystrophy, a progressive neuromuscular disorder associated with severe functional decline. The clinical portfolio reflects interest in therapies aimed at improving disease management in affected children and young people.
- Duchenne Muscular Dystrophy
- Neuromuscular disease
- Pediatric treatment
This area highlights the company’s involvement in therapeutic development for inherited disorders with substantial unmet medical need.
Hemophilia A and Bleeding Disorders
Another key therapeutic area is hemophilia A, where BioMarin supports clinical research related to long-term management and follow-up in patients with inherited bleeding disorders. The focus is on maintaining safety and treatment experience in individuals previously exposed to gene-based or factor-directed approaches.
- Hemophilia A
- Inherited bleeding disorders
- Long-term follow-up
These studies place the sponsor within the field of rare hematologic disease research.
Phenylketonuria and Metabolic Disorders
BioMarin’s research portfolio includes phenylketonuria, a rare metabolic condition requiring ongoing dietary and pharmacologic management. The company’s work in this area reflects interest in improving treatment options for adolescents living with inherited amino acid metabolism disorders.
- Phenylketonuria
- Metabolic disease
- Adolescent care
This therapeutic domain broadens the sponsor’s rare disease focus beyond growth and neuromuscular conditions.
